Near-term opportunities (12–24 months) include single-drug HA or chitosan films/wafers for clearly defined lesions, xerostomia coatings guided by mucin-synergism metrics, and pilot randomized trials built on standardized panels (ΔG′ with mucin, wet-peel/tensile, TEER-recovery). This evidence concerns the gene MUC5AC and xerostomia.